secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-07-22T12:30:27+00:00
Accession:  0001493152-26-034183
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Technologies partners with Pictor to develop asthma/COPD diagnostics
--------------------------------------------------------------------------------

- Collaboration integrates bioAffinity's flow cytometry with Pictor's targeted proteomic platform for lung inflammation tests.
- Tests aim to match asthma/COPD patients with personalized treatments; asthma/COPD affect 40M Americans and 650M worldwide.
- Global asthma/COPD therapeutics market projected to exceed $108B in 2026 and $155B by 2030.
- bioAffinity will own IP for tests developed; Pictor retains its platform IP and owns new platform inventions.
- Tests initially offered as Laboratory Developed Tests under CLIA; no financial terms disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226034183/0001493152-26-034183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226034183/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-034183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer